Loading

对于冠状病毒,出现有效疫苗希望渺茫 【中英对照翻译】

新闻来源:英國天空新聞|作者: Thomas Moore;

翻译、简评:Victory|校对:感恩|审核:InAHurry|PAGE:玄天生;

简评:

全世界人民被中共病毒困在家里长达大半年,身心已经接近忍受极限,所有人都对有效疫苗翘首以盼。然而到目前为止,很多疫苗都在不同实验阶段出现不良反应。

但是问题的本质并不在于此。闫博士作为专业人士说过,对于这个病毒,出现有效疫苗希望渺茫。因为病毒是中共精心研发的生物武器。而且中共不会只有一个病毒株,而是一个系列。因此,中共很可能有其他暂时未放出的病毒。世界各国只把精力放在研发疫苗上,而对病毒真相置之不理,这无异于“抱薪救火”,因为病毒还会源源不断地被中共放出来。唯一的,彻底解决办法,就是是“釜底抽薪”,灭掉中共。

原文翻译

Coronavirus: First vaccines 'unlikely to end pandemic' - says UK vaccines chief

英国疫苗部门负责人说:冠状病毒首批疫苗“不太可能终结大流行”

Kate Bingham, who heads the Vaccine Taskforce, says uncertainties remain over how much protection vaccines give and for how long.

疫苗研发团队负责人凯特·宾厄姆(Kate Bingham)说,疫苗能提供多少保护以及持续多长时间仍存在不确定性

By Thomas Moore, science correspondent|报道:Thomas Moore,科学记者

Chair of UK vaccine taskforce 'optimistic' about trials

英国疫苗研发团队负责人对试验表示“乐观”

The first wave of COVID-19 vaccines are unlikely to end the pandemic, the UK vaccines chief has told Sky News.

英国疫苗负责人告诉天空新闻,第一批新冠疫苗不太可能结束大流行。

The UK has 340 million doses of six prototype vaccines in its stockpile - more than any other country.

英国有3.4亿剂库存的6种原型疫苗,这多于其他任何国家。

But Kate Bingham, who heads the Vaccine Taskforce, said uncertainties remain over how much protection they give and for how long. Further candidates, including some in early development, will still be needed.

但疫苗研发团队负责人凯特·宾厄姆(Kate Bingham)说,疫苗能提供多少保护以及持续多长时间仍存在不确定性。仍需要包括一些处于早期研发阶段的更多的候选疫苗。

"We are not done," she said in an exclusive interview.

她在一次独家采访中说:“我们还没完成任务”。

Image:Two vaccines are expected to release data from key phase 3 clinical trials within weeks

图片:预计数周内将公布两种疫苗关键的三期临床试验数据

"The reason we've gone for a range of vaccines is to maximise our chances that we will have at least one successful vaccine that works in the population who are most vulnerable.

“我们研发一系列疫苗的原因是为了最大程度的确保我们使至少有一种疫苗会在最脆弱人群中有效。”

"We are always looking for additional vaccines for delivery at different times or with a different immune profile."

“我们一直在寻找额外的疫苗,以便应用在不同的时间或有不同的免疫特性。 ”

Two vaccines, made by Oxford University/AstraZeneca and BioNTech/Pfizer, are expected to release data from key phase 3 clinical trials within weeks.

分别由牛津大学/阿斯利康制药和BioNTech(德国生物技术公司)/辉瑞研发的两种疫苗,有望在几周内公布关键的3期临床试验数据。

They should show whether the vaccines stop the virus spreading or just alleviate symptoms.

数据将显示疫苗是阻止病毒传播还是仅仅缓解症状。

But Ms Bingham said even a vaccine that reduces the severity of disease in vulnerable patients would still be worthwhile.

但是宾厄姆女士说,即使这只是一种可以缓减脆弱患者病情的疫苗,仍然是值得的。

"A partially effective vaccine is better than no vaccine at all," she continued.

她还说,“部分有效的疫苗总比没有疫苗好,”

"Flu vaccines are 50% effective, but they are widely used and have a big impact on reducing the clinical impacts of flu in the population."

“流感疫苗有50%的有效性,但它们被广泛使用,对减少流感在人群中的临床影响有巨大作用。”

Ms Bingham has joined a trial of the Novavax vaccine at the Royal Free Hospital in London. She does not know whether it was the active vaccine or a saline dummy.

宾厄姆女士参加了伦敦皇家自由医院的诺瓦瓦克斯疫苗试验。她不知道她被接种的是活性疫苗还是盐水假疫苗对照。

More than 270,000 people have so far signed up to the Vaccine Research Registry in the hope of joining trials. More volunteers from ethnic minorities are needed to test vaccines in a diverse population.

到目前为止,已有超过27万人在疫苗研究登记处注册,希望能参加试验。需要更多少数族裔志愿者,以便可以在不同人群中测试疫苗。

Image:Kate Bingham thinks a partially effective vaccine is better than no vaccine at all

图片:宾厄姆女士认为部分有效的疫苗总比没有疫苗好

Ms Bingham said the prolonged pause of a US trial of the Oxford vaccine, due to a possible adverse event, should not delay a decision by UK regulators on whether it was safe and effective to roll out on this side of the Atlantic. Trials in the UK and Brazil have already been cleared to continue.

宾厄姆女士表示,由于可能出现不良反应,美国延长了对牛津疫苗的试验暂停时间,这不应该推迟英国监管机构就是否安全有效地在本地推广该疫苗做出决定。在英国和巴西的试验已经获准继续进行。

She said she understood the desperation for a vaccine, particularly with the prospect of long local lockdowns over winter.

她说,她理解人们对疫苗的渴望,特别是考虑到当地可能会在冬季实施长期禁闭政策。

"The comfort I can give, is we have four of our six vaccines now in phase 3 efficacy clinical trials, so we have vaccines that have progressed rapidly into that final stage of efficacy testing," she said.

她说“我可以给人们的安慰是,我们的6种疫苗中有4种正在进行三期临床试验,所以我们的疫苗已经迅速进展到效力测试的最后阶段。”

"We haven't seen any serious safety signals that have stopped these vaccines completely. There will of course be safety issues, but these are carefully monitored."

“我们还没有看到任何可造成终止这些疫苗的严重安全迹象。当然会有安全问题,但这些都是被仔细监控的。 ”

Professor Jonathan Ball, a vaccine expert at Nottingham University, said everything rides on good results from the phase 3 trials. Antibody levels fall quickly after real COVID infection. If the same happens with a vaccine it may only protect for a month or two.

诺丁汉大学的疫苗专家乔纳森·鲍尔(Jonathan Ball)教授说,一切都取决于三期试验的良好结果。在真正的COVID感染后抗体水平迅速下降。如果同样的情况发生在疫苗上,它可能只提供一两个月的保护。

"At the moment we have no protection against COVID-19 at all - and for elderly people, particularly those with diseases like obesity and diabetes, this is a serious illness.

“目前我们对COVID-19完全没有保护,对于老年人,特别是那些患有肥胖和糖尿病的人来说,这是一种严重的疾病。”

"So if we can give hope to people, that's important, but it can't be false hope.

“所以,如果我们能给人们希望,这很重要,但这不能是虚假的希望。”

"We have to be assured that those vaccines do what we intend."

他说:“我们必须确保这些疫苗符合我们的预期目标。”

编辑 【喜马拉雅战鹰团】